The role of dehydroepiandrosterone sulphate and testosterone in erectile dysfunction in patients treated with 5 alpha reductase inhibitors

Sofronievska, Maja (2021) The role of dehydroepiandrosterone sulphate and testosterone in erectile dysfunction in patients treated with 5 alpha reductase inhibitors. Knowledge International Journal (KIJ), 46 (4). pp. 505-510. ISSN 1857-923X / 2545 - 4439 printed

Text The role of dehydroepiandrosterone sulphate and testosterone in ED.pdf Download (1MB)

Abstract

Abstract: The pharmacological treatment of benign prostatic hyperplasia involves the use of mainly two groups of
drugs: selective alpha 1 blocker and 5 alpha reductase inhibitors (5ARI). In patients who undergo 5ARI pharmacotreatment, adverse effects such as sexual disturbances such as erectile dysfunction and decreased libido may occur.
The purpose of this study is to investigate the occurrence of these side effects, particularly erectile dysfunction in
order to predict and overcome them more easily. We conducted a controlled prospective pharmaco-epidemiological
study to evaluate the side effects with the use of 5ARI in 250 men with benign prostatic hyperplasia (BPH). Erectile
function was assessed at the time of the initiation of therapy and at the time of active use of therapy in two
consecutive periods of 6 months and 12 months. We evaluated two groups of patients: the control group of patients
treated with alpha 1 blocker (tamsulosin), and the investigated group of patients treated with combination therapy of
alpha 1 blocker (tamsulosin) and 5 alpha reductase inhibitors (dutasteride). The evaluation was conducted through
questionnaires: IPSS (International Prostate Score System) to calculate the symptoms of benign prostatic hyperplasia
(light, medium or severe) and IIEF-5 (International Index for Erectile Function-5) questionnaire for calculating
erectile function. During the study measurement of serum levels of testosterone and dehydroepiandrosterone
sulphate were performed respectively. Statistical results of nonparametric group analysis showed that erectile
dysfunction appeared in 27 patients (22.5%) in the investigated group after 6- and 12-months therapy respectively
which was statistically significant (p<0,05). Twenty six of these patients (96,3%) have had lowered testosterone and
dehydroepiandrosterone sulphate serum levels (p<0,05). As a conclusion we recommend investigation of
testosterone and DHEAS serum levels prior to starting therapy should be considered valuable in order to avoid 5ARI
related erectile dysfunction.
Keywords: BPH, erectile function, testosterone, dehydroepiandrosterone-sulphat

Item Type:	Article
Subjects:	Medical and Health Sciences > Basic medicine Medical and Health Sciences > Clinical medicine Medical and Health Sciences > Health sciences Medical and Health Sciences > Other medical sciences
Divisions:	Faculty of Medical Science
Depositing User:	Maja Sofronievska
Date Deposited:	15 Aug 2022 09:20
Last Modified:	15 Aug 2022 09:20
URI:	https://eprints.ugd.edu.mk/id/eprint/29976

Actions (login required)

View Item